Emphasizes the need to differentiate true resistant hypertension from pseudoresistance and to individualize treatment.
True refractory hypertension is relatively rare, but the causes of pseudoresistance are many. Thus, all patients should be considered medically treatable until proved otherwise. Initial workup should seek to determine whether the patient, the physician, or the hypertension is resistant. And one must make sure that therapy is indeed tailored to the patient's individual pathophysiology.
Robert C. Tarazi (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: